110 results about "Muscle relaxant" patented technology

A pain relief lollipop comprises a candy matrix comprising (a) an opioid agonist, (b) an N-methyl-D-aspartate receptor antagonist different from the opioid agonist, (c) gabapentin, or a pharmaceutically acceptable salt thereof, and, optionally, a muscle relaxant, sedative, anxiolytic, and/or antidepressant. A patient can self-administer small amounts of the pain relief drug as needed by simply licking or sucking on the lollipop in response to his subjective experience of pain.

The present invention relates to a composition consisting of a combination of peptides that regenerate the dermal matrix and a rapid acting muscle relaxant derived from the extract of the plant, Acemella oleracea. By limiting cutaneous deformation caused by the contraction of facial muscles the extract increases the efficiency of the peptides in reducing expression lines.

The present embodiments relate to topically delivered compounded medications. A transdermal cream may provide the effective topical administration of multiple medications simultaneously; may include low concentrations of local anesthetics, a NSAID, an anticonvulsant, and/or other active ingredients; and may include lidocaine, prilocaine, meloxicam, and lamotrigine and/or topiramate. Alternatively, the transdermal cream may include a lidocaine/prilocaine base cream to which is added a fine powder of one or more ground up medications to form a compounded medication. The compounded medication in powder form may be generated from grinding up tablets of NSAIDs, anticonvulsants, nerve depressants, antidepressants, muscle relaxants, NMDA receptor antagonists, opiate or opioid agonists, and/or other agents. The compounded medication in powder form may include meloxicam, lamotrigine, topiramate, other active ingredients, and DMSO or Sterile Water for Irrigation. In another aspect, the present embodiments relate to methods of compounding medications and transdermal creams or gels.

The invention provides a bromide type muscle relaxant, which mainly comprises a method for synthesizing rocuronium bromide, vecuronium bromide, pancuronium bromide and pipecuronium bromide , and is mainly characterized by adopting a ketene as an acylating agent during the process of transforming 5Alpha-androstane -2-alkene-17-alkone to 17-acetoxyl group-5Alpha- androstane-2, and 16-diene, adopting a stress kettle as a reactor when realizing the step of ring-opening and condensation of the 2 Alpha and 3 Alpha-epoxy compound, and adding a solid catalyst and a desiccant in the last step of operation of rocuronium bromide to greatly improve the reaction yield and the quality of products. The technology provided by the invention can shorten the synthesis time of the bromide type muscle relaxant, simplify the operation steps, improve the quality of products and reduce the production cost.

The present invention relates to the compound of formula

which is 4-hydroxy-4-methyl-piperidine-1-carboxylic acid(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide, and to pharmaceutically acceptable acid addition salts thereof. It has been found that the compound is useful for the treatment or prevention of Alzheimer's disease, Parkinson's disease, Huntington's disease, neuroprotection, schizophrenia, anxiety, pain, respiration deficits, depression, ADHD (attention deficit hyper-activity disorder), drug addiction to amphetamines, cocaine, opioids, ethanol, nicotine, or cannabinoids, or for the treatment of asthma, allergic responses, hypoxia, ischemia, seizure, substance abuse, or for use as muscle relaxants, antipsychotics, antiepileptics, anticonvulsants and cardioprotective agents.

The present invention provides compositions and methods of using stereospecific benzodiazepine derivatives, their salts and prodrugs for the treatment of anxiolytic or convulsant disorders having the side effects of reduced alcohol craving in human alcoholics and a concomitant reduced sedative, hypnotic, muscle relaxant and ataxic side-effects. The invention further provides pharmaceutical compositions for treatment of anxiolytic and convulsant disorders in subjects in need thereof, comprising a compound, prodrug or a salt having a chemical structure represented by any one of Formula I-XXI and a pharmaceutically-acceptable carrier.

The invention relates to relatively short peptides (termed α-conotoxins herein), about 10-25 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds. The α-conotoxins, as described herein, are useful for as neuromuscular blocking agents, such as muscle relaxants.

The invention discloses a design of a comprehensive extraction process for barberry plant resources. Berbamine hydrochloride, jatrorrhizine hydrochloride, palmatine hydrochloride and a muscle relaxant are synchronously, efficiently and comprehensively extracted while berberine hydrochloride is extracted, and berbamine is used as a raw material for synthesizing an analgesic drug. Therefore, the barberry plant resources are fully utilized, the added medicinal value is increased, and the comprehensive utilization rate of medicinal barberry is increased. For a traditional Chinese medicine, one medicinal part is often utilized only and other parts are discarded. Various components in the barberry are synchronously extracted and comprehensively utilized, so that the economic value of the barberry is greatly increased.

The invention describes antibiotics, muscle relaxants and plant extracts that have neuromuscular blockade effects as well as methods of use thereof. These compounds can be used in the same clinical settings as botulinum toxin and may be used topically, thereby providing an advantage over botulinum toxin in terms of application and ease of use. The compounds can be used in pharmaceutical compositions for the treatment of involuntary muscle spasms and neuropathic pain and in cosmetic compositions for the treatment of facial wrinkles. Also provided are kits useful for therapeutic and/or cosmetic applications.

A pharmaceutical composition comprising an .alpha.3.beta.4 nicotinic receptor antagonist effective to diminish the brain-derived feeling of pleasure due to increased dopamine in the pleasure-reward center of the brain typically associated with administration of an opioid agonist analgesic, a muscle relaxant, an anti-seizure medication, an anxiolytic drug, an amphetamine, a central nervous system stimulant, a tetrahydrocannabinol or that associated with an otherwise pleasurable or self-reinforcing behavior.

The present invention comprises an all-natural composition of matter and methods of delivering nutrients, medicines, pain relievers, antioxidants, antidotes, antibiotics and various active ingredients and supplements directly to the affected area of the body. The all-natural carrier composition consists essentially of the combination of a natural oil, water, salt(s), natural emulsifier, natural sugar(s), plant extracts, natural acid(s), starch and natural flavor(s). The active substances that are mixed with the all-natural carrier composition, include, but are not limited to, drugs, vitamins, minerals, antibiotics anti fungal agents, antioxidants, diuretics, allergy medicines, anti-inflammatory agents, muscle relaxers, pain reducers, diabetic drugs, neuropathy drugs, chemotherapy agents, arthritis drugs, lotions for eczema, shingles, psoriasis, skin rash; herbal medicines, erectile dysfunction drugs, hormones, cholesterol drugs, essential fatty acids, and the like. The all-natural carrier composition facilitates the penetration of active substances into the dermal layer of the skin.

The invention aims at providing an anaesthetic balance control device. The device comprises a data filter module and a drug balance control module. Pre-stored electrocerebral indexes, noxious stimulation data drug usage data are divided into electrocerebral index-sedative data and noxious stimulation data-sedative data. Corresponding drug target control indexes are selected according to electrocerebral index and noxious stimulation data changes in certain period, threshold values are preset, and injection of muscle relaxants are increased or stopped based on the set threshold values. Meanwhile, bispectral index, noxious stimulation data, neuromuscular retarding depth data change tendency slope and the like can be analyzed dynamically, and transverse balance adjusting control is performed on three signals. The invention further provides a work method of the device. According to the device and the method, the problem the imbalanced usage of three drugs is solved, effects of individual differences are prevented, the safety during anesthesia is guaranteed to the largest extent, and good social values and application prospects are provided.

Orally active benzodiazepine derivatives and their salts are disclosed. These compounds and their salts have anxiolytic and anticonvulsant activity with reduced sedative/hypnotic/muscle relaxant/ataxic effects.

Human muscle tissues involve striated and smooth muscles. Each muscle tissue possesses its own special function. Differences of physiology functions among the muscle tissues are mainly determined by their various initiation and signal transmission systems, defined as the pre-muscle molecular motor mechanism, or initiating and regulating mechanism. The current medications, drugs, and therapies for diseases and symptoms related abnormal increased muscle tone or excessive muscle contraction are aimed just at the pre-muscle molecular motor mechanisms, whereas without directly intending to effect on the muscle molecular motor mechanism i.e. the contractile apparatus mechanism at all, which, however, is in common for all kinds of muscle tissues. The muscle molecular motor mechanism mainly involves recycling of actin-myosin filament cross-bridge formation and sliding movement. In the process, bio-energy provided by ATP hydrolysis is necessarily required. Therefore, abnormal increased muscle tone or excessive contraction of muscle tissues under diseased conditions may be modified by inhibition of the muscle molecular motor with the actin-myosin ATPase inhibitor, which blocks hydrolysis of ATP, then reduces release of bio-energy for the muscle contraction.

Our studies in vitro and in vivo have demonstrated that BDM, an ATPase inhibitor, thereby, its analogues, derivatives, and other chemicals possessing similar effect on ATPase may be used as bio-energy muscle relaxants (general muscle relaxants).

A topical pharmaceutical formulation made up of nimesulide or a pharmaceutically acceptable derivative of nimesulide, together with thiocolchicoside or a pharmaceutically acceptable derivative of thiocolchicoside. The present invention more particularly relates to pharmaceutical combinations of nimesulide and thiocolchicoside, in the form of topical gels, ointments, cream, sprays, or lotions with anti-inflammatory, analgesic, and myorelaxant activities.

The invention discloses a mivacurium chloride composition as well as a preparation method and an application thereof. The mivacurium chloride composition consists of mivacurium chloride, a compound A,a compound B as well as an optional compound C and an optional compound D, wherein in terms of total weight of the mivacurium chloride composition, the compound A accounts for 0.001-0.15wt%, preferably 0.001-0.13wt%, and more preferably 0.001-0.1wt%; and the compound B accounts for 0.001-0.15wt%, preferably 0.006-0.15wt%, and more preferably 0.01-0.15wt%. The mivacurium chloride composition provided by the invention is good in stability in long-term preservation, relatively low in histamine release action and low in toxic and side effects.

This invention is a novel pharmaceutical composition comprising flurbiprofen or a pharmaceutically acceptable salt thereof in combination with an α-2 adrenergic receptor agonist or a gamma-aminobutiric acid receptor agonist with anti-inflammatory, analgesic and myorelaxant activity.

The present invention provides chimeric receptors that include an extracellular domain from a metabotropic glutamate receptor and a non-native signal peptide, e.g., a calcium receptor signal peptide. The invention also includes methods of preparing such chimeric receptors, and methods of using such receptors to identify and characterize compounds which modulate the activity of metabotropic glutamate receptors. The invention also relates to compounds and methods for modulating metabotropic glutamate receptor activity and binding to metabotropic glutamate receptors. Modulation of metabotropic glutamate receptor activity can be used for different purposes such as treating neurological disorders and diseases, inducing an analgesic effect, cognition enhancement, and inducing a muscle-relaxant effect.

Provided are a composition and method for vaginal therapy. The composition includes a delivery compound and a pharmaceutically active agent dispersed in the delivery compound. The pharmaceutically active agent includes a centrally acting muscle relaxant. The method for vaginal therapy includes preparing a composition including a pharmaceutically active agent dispersed in a delivery compound, and administering the composition intravaginally. The pharmaceutically active agent includes a muscle relaxant. Another method includes administering the composition extravaginally and then administering the composition intravaginally.

The present embodiments may relate to topically delivered compounded medications for the treatment of scar tissue, skin disorders, and/or other ailments. In one aspect, a transdermal cream or gel may provide for the effective administration of multiple medications simultaneously. Preferably, a silicone-based gel may be provided as a base composition and may have a non-zero percentage of silicone or silicone variant. The silicone-based gel may comprise cyclopentasiloxane, polysilicone-11, dimethicone, and C30-45 alkyl cetearyl dimethicone crosspolymer, and include several active ingredients, such as glucocorticoids, antihistamines, and nerve depressants. The silicone-based gel may include a combination of fluticasone, loratadine, and gabapentin. The concentrations of fluticasone and loratadine may be relatively low, while that of gabapentin moderately high. The silicone-based gel may also have one or more local anesthetics, such as prilocaine and/or lidocaine. The silicone-based gel may include additional active ingredients, such as NSAIDs, anticonvulsants, antidepressants, muscle relaxants, and/or other active ingredients.